Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

In the last two years, clinical trials with blocking antibodies to the negative checkpoint regulators CTLA-4 and PD-1 have rekindled the hope for cancer immunotherapy. Multiple negative checkpoint regulators protect the host against autoimmune reactions but also restrict the ability of T cells to ef...

Full description

Bibliographic Details

Published in:	Frontiers in immunology Vol. 6; p. 418
Main Authors:	Le Mercier, Isabelle, Lines, J. Louise, Noelle, Randolph J.
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 21.08.2015
Subjects:	Autoimmunity BTLA cancer immunotherapy Immunology LAG-3 TIGIT TIM-3 VISTA autoimmunity LAG-3 cancer immunotherapy BTLA negative checkpoint regulators TIGIT TIM-3
ISSN:	1664-3224, 1664-3224
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!